Risk of Pseudophakic Cystoid Macular Edema in Fellow-Eye Cataract Surgeries

Autor: Ahmed F. Shakarchi, Mohamed K. Soliman, Yit C. Yang, Ahmed B. Sallam

Publikováno v: Ophthalmology. 130:640-645

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f68965718c4e39950991ba1090fe9c9b
https://doi.org/10.1016/j.ophtha.2023.01.019

Visual outcomes and complications of combined vs sequential cataract surgery and pars plana vitrectomy: multicenter database study

Autor: Abdelrahman M, Elhusseiny, Mohamed K, Soliman, Ahmed F, Shakarchi, Yousef A, Fouad, Yit C, Yang, Ahmed B, Sallam

Publikováno v: Journal of Cataract and Refractive Surgery. 49:142-147

To compare the visual outcomes and rates of intraoperative complications, in eyes that underwent combined cataract extraction (CE) and pars plana vitrectomy (PPV) (combined group) to those that underwent sequential surgery (sequential group).Multicen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd188932d2ae6102d3eb232227ca239
https://doi.org/10.1097/j.jcrs.0000000000001059

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

Autor: David R. Lally, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier

Publikováno v: Eye. 37:1242-1248

Objective Post-hoc analysis to compare the outcomes of brolucizumab 6 mg vs. aflibercept 2 mg in neovascular age-related macular degeneration (nAMD) patients with early persistent retinal fluid in HAWK and HARRIER. Methods After 3 monthly loading dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::98f7889372133cf46bc803bcf6eb3d3d
https://doi.org/10.1038/s41433-022-02092-5

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

Autor: Becky Pennington, Andrew Metry, Edith Poku, Joana C. Vasconcelos, Caroline Murphy, Sobha Sivaprasad, John Brazier, Philip G Hykin, Joanna Kelly, Andrew J. Lotery, A Toby Prevost, Abualbishr Alshreef, Yit C. Yang, Michael Williams, Laura Flight

Publikováno v: Pennington, B, Alshreef, A, Flight, L, Metry, A, Poku, E, Hykin, P, Sivaprasad, S, Prevost, A T, Vasconcelos, J C, Murphy, C, Kelly, J, Yang, Y, Lotery, A, Williams, M & Brazier, J 2021, ' Cost effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study ', PharmacoEconomics, vol. 39, no. 8, pp. 913–927 . https://doi.org/10.1007/s40273-021-01026-5
Pharmacoeconomics

Background We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. Methods We calculated costs and qual

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f4ebebeaf218c3f06bcc4fab3966179
https://doi.org/10.1007/s40273-021-01026-5

Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery

Autor: Louise Downey, Ian Pearce, Winfried M Amoaku, Clare Bailey, Faruque Ghanchi, Yit C. Yang, Richard Gale, Robin Hamilton, Sajjad Mahmood, Jenny Nosek, Geeta Menon

Publikováno v: Clinical Ophthalmology. 14:1315-1328

An aging population leads to increasing demand for medical retina services with chronic diseases being managed in long-term care pathways. Many hospital services struggle to deliver efficient and effective MR care due, at least in part, to infrastruc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce79d8617eb697dcceac22d043d46992
https://doi.org/10.2147/opth.s233061